Content deleted Content added
Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: {{cascite}} {{fdacite}} StdInChI StdInChIKey. |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Ph |
||
Line 1: | Line 1: | ||
{{drugbox |
{{drugbox |
||
| verifiedrevid = |
| verifiedrevid = 401812733 |
||
| IUPAC_name = (''E'')-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid |
| IUPAC_name = (''E'')-5-([4-(2-carboxyethylcarbamoyl)phenyl]diazenyl)-2-hydroxybenzoic acid |
||
| image = Balsalazide.png |
| image = Balsalazide.png |
||
Line 8: | Line 8: | ||
| InChI = 1/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ |
| InChI = 1/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ |
||
| InChIKey = IPOKCKJONYRRHP-FMQUCBEEBN |
| InChIKey = IPOKCKJONYRRHP-FMQUCBEEBN |
||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChI = 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ |
| StdInChI = 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+ |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|||
| StdInChIKey = IPOKCKJONYRRHP-FMQUCBEESA-N |
| StdInChIKey = IPOKCKJONYRRHP-FMQUCBEESA-N |
||
| CAS_number = 80573-04-2 |
| CAS_number = 80573-04-2 |
||
Line 17: | Line 19: | ||
| DrugBank = APRD00141 |
| DrugBank = APRD00141 |
||
| C=17 | H=15 | N=3 | O=6 |
| C=17 | H=15 | N=3 | O=6 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|||
| ChemSpiderID=10662422 |
| ChemSpiderID=10662422 |
||
| molecular_weight = 357.318 g/mol |
| molecular_weight = 357.318 g/mol |
Revision as of 18:38, 11 December 2010
Clinical data | |
---|---|
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | <1% |
Protein binding | ≥99% |
Elimination half-life | 12hr |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.117.186 |
Chemical and physical data | |
Formula | C17H15N3O6 |
Molar mass | 357.318 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. It is also sold in generic form in the US by several generic manufacturers.
It is usually administered as the disodium salt.
Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
References
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11709512, please use {{cite journal}} with
|pmid=11709512
instead.